Skip to main content
Search
Site Search
Ireland | en
Choose Location
Americas
Asia Pacific
Europe
International
Middle East & Africa
Argentina |
Español
Brazil |
Português
Canada |
English
Canada |
Français
Andean & CAC |
Español
Colombia |
Español
Mexico |
Español
United States |
English
Australia |
English
Hong Kong S.A.R. |
繁體中文
India |
English
Indonesia |
English
Japan |
日本語
Korea |
한국어
Mainland China |
中文
Malaysia |
English
Philippines |
English
Singapore |
English
Taiwan |
繁體中文
Thailand |
ภาษาไทย
Austria |
Deutsch
Belgium |
Français
Belgium |
Nederlands
Bulgaria |
Български
Czech Republic |
Česky
Czech Republic |
English
Denmark |
Dansk
Estonia |
Eesti
Finland |
Suomalainen
France |
Français
Germany |
Deutsch
Greece |
Ελληνικά
Hungary |
Magyar
Ireland |
English
Italy |
Italiano
Latvia |
Latvian
Lithuania |
Lithuanian
Netherlands |
Nederlands
Norway |
Norsk
Poland |
Polski
Portugal |
Português
Romania |
Română
Russia |
Русский
Serbia |
Srpski
Slovakia |
Slovensky
Slovenia |
Slovenščina
Slovenia |
English
Spain |
Español
Sweden |
Svenska
Switzerland |
Deutsch
Switzerland |
Français
Türkiye |
Türkçe
Ukraine |
українська
United Kingdom |
English
Global |
English
Novartis Foundation |
English
Egypt |
English
Israel |
עברית
Saudi Arabia |
العربية
South Africa |
English
Ireland
Choose Location
europe
Americas
Asia Pacific
Europe
International
Middle East & Africa
Argentina |
Español
Australia |
English
Austria |
Deutsch
Belgium |
Français
Belgium |
Nederlands
Brazil |
Português
Bulgaria |
Български
Canada |
English
Canada |
Français
Andean & CAC |
Español
Colombia |
Español
Czech Republic |
Česky
Czech Republic |
English
Denmark |
Dansk
Egypt |
English
Estonia |
Eesti
Finland |
Suomalainen
France |
Français
Germany |
Deutsch
Greece |
Ελληνικά
Hong Kong S.A.R. |
繁體中文
Hungary |
Magyar
India |
English
Indonesia |
English
Ireland |
English
Israel |
עברית
Italy |
Italiano
Japan |
日本語
Korea |
한국어
Latvia |
Latvian
Lithuania |
Lithuanian
Mainland China |
中文
Malaysia |
English
Mexico |
Español
Netherlands |
Nederlands
Norway |
Norsk
Global |
English
Novartis Foundation |
English
Philippines |
English
Poland |
Polski
Portugal |
Português
Romania |
Română
Russia |
Русский
Saudi Arabia |
العربية
Serbia |
Srpski
Singapore |
English
Slovakia |
Slovensky
Slovenia |
Slovenščina
Slovenia |
English
South Africa |
English
Spain |
Español
Sweden |
Svenska
Switzerland |
Deutsch
Switzerland |
Français
Taiwan |
繁體中文
Thailand |
ภาษาไทย
Türkiye |
Türkçe
Ukraine |
українська
United Kingdom |
English
United States |
English
Menu
About
Novartis in Ireland
Country Leadership Team
Contact
About
Patients and Caregivers
Novartis Commitment to Patients and Caregivers
Education and Awareness
Patient Resources
Adverse Event Reporting
Novartis Societal Impact
Patients and Caregivers
Healthcare Professionals
Healthcare professional country resource
Adverse Event Reporting
Novartis Clinical Trials
Novartis Ireland travel and Expenses Guidance
Healthcare Professionals
ESG
Ethical Behavior
Code of Ethics
SpeakUp
Ethics, Risk and Compliance
Environmental Sustainability
ESG
News
News Archive
Stories
Contacts
News
Careers
Career Search
Working in Novartis Ireland
Learning and Development
Early Talent
How We Work
Well-being
Diversity & Inclusion
Awards and Recognition
Careers
Investors
Financial Data
Coronavirus
Coronavirus
Home
Stories
Story Navigation
All Topics
Education & Awareness
Corporate
People and Culture
icon
List View
Corporate
Mar 17, 2022
A visual tour of scientific strategies for combating coronavirus
Corporate
Corporate
Mar 17, 2022
Novartis Ireland providing a broad range of initiatives to respond to communities impacted by COVID-19
Corporate
Corporate
Mar 17, 2022
Novartis Partnership with Trinity Centre for People with Intellectual Disabilities
Corporate
Corporate
Mar 17, 2022
Novartis opens facility for innovative cell and gene therapies in Switzerland
Corporate
Corporate
Mar 17, 2022
Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence
Corporate
Corporate
Mar 17, 2022
Novartis Signs Collaboration Agreement to Fund Medtech Development of Low Cost Eye Monitor
Corporate
Pagination
‹
Previous page
1
2
›
Next page